Epitope mapping: The first step in developing epitope-based vaccines

BioDrugs

Volumn 21, Issue 3, 2007, Pages 145-156

  Gershoni, Jonathan M ^a   Roitburd Berman, Anna ^a   Siman Tov, Dror D ^a   Freund, Natalia Tarnovitski ^a   Weiss, Yael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ANTIGEN; DOCKING PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY; VACCINE;

ALGORITHM; ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN STRUCTURE; B LYMPHOCYTE; BACTERIOPHAGE; BINDING ASSAY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG COST; EPITOPE MAPPING; GENETIC VARIABILITY; GOLD STANDARD; IMMUNE RESPONSE; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; COMBINATORIAL CHEMISTRY TECHNIQUES; EPITOPE MAPPING; EPITOPES; GENETIC TECHNIQUES; HUMANS; MODELS, MOLECULAR; MUTAGENESIS; VACCINES;

EID: 34249725007     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721030-00002     Document Type: Review

References (88)

1. Henderson DA. Smallpox eradication. Public Health Rep 1980; 95: 422-6
2. Henderson DA. Eradication: lessons from the past. Bull World Health Organ 1998; 76 Suppl. 2: 17-21
3. Hovi T. Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001; 19: 2268-72
4. John TJ. The final stages of the global eradication of polio. N Engl J Med 2000; 343: 806-7
5. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341: 2068-74
6. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225-32
7. Olson JK, Croxford JL, Calenoff MA, et al. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001; 108: 311-8
8. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62: 2536-44
9. Babai I, Samira S, Barenholz Y, et al. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I: vaccine characterization and efficacy studies in mice. Vaccine 1999; 17: 1223-38
10. Nemchinov LG, Liang TJ, Rifaat MM, et al. Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol 2000; 145: 2557-73
11. Arthur LO, Pyle SW, Nara PL, et al. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A 1987; 84: 8583-7
12. Sun DX, Seyer JM, Kovari I, et al. Localization of protective epitopes within the pilin subunit of the Vibrio cholerae toxin-coregulated pilus. Infect Immun 1991; 59: 114-8
13. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59
14. Parren PW, Moore JP, Burton DR, et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. Aids 1999; 13 Suppl. A: S137-62
15. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-11
16. Berkower I, Smith GE, Giri C, et al. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation. J Exp Med 1989; 170: 1681-95
17. Fust G. Enhancing antibodies in HIV infection. Parasitology 1997; 115 Suppl.: S127-40
18. Jacotot E, Krust B, Callebaut C, et al. HIV-1 envelope glycoproteins-mediated apoptosis is regulated by CD4 dependent and independent mechanisms. Apoptosis 1997; 2: 47-60
19. Montefiori DC. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin Immunopathol 1997; 18: 371-90
20. Steere AC, Gross D, Meyer AL, et al. Autoimmune mechanisms in antibiotic treatment-resistant Lyme arthritis. J Autoimmun 2001; 16: 263-8
21. Trollmo C, Meyer AL, Steere AC, et al. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1 alphaL is a partial agonist for outer surface protein A-reactive T cells. J Immunol 2001; 166: 5286-91
22. Willett TA, Meyer AL, Brown EL, et al. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci U S A 2004; 101: 1303-8
23. Van Regenmortel MH, Pellequer JL. Predicting antigenic determinants in proteins: looking for unidimensional solutions to a three-dimensional problem? Pept Res 1994; 7: 224-8
24. Cai X, Dass C. Structural characterization of methionine and leucine enkephalins by hydrogen/deuterium exchange and electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 1-8
25. Laporte SA, Boucard AA, Servant G, et al. Determination of peptide contact points in the human angiotensin II type I receptor (AT1) with photosensitive analogs of angiotensin II. Mol Endocrinol 1999; 13: 578-86
26. Sagan S, Quancard J, Lequin O, et al. Conformational analysis of the C-terminal Gly-Leu-Met-NH2 tripeptide of substance P bound to the NK-1 receptor. Chem Biol 2005; 12: 555-65
27. Geysen HM, Meloen RH, Barteling SJ, et al. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci U S A 1984; 81: 3998-4002
28. Cretich M, Damin F, Pirri G, et al. Protein and peptide arrays: recent trends and new directions. Biomol Eng 2006; 23: 77-88
29. Poetz O, Ostendorp R, Brocks B, et al. Protein microarrays for antibody profiling: specificity and affinity determination on a chip. Proteomics 2005; 5: 2402-11
30. Andresen H, Zarse K, Grotzinger C, et al. Development of peptide microarrays for epitope mapping of antibodies against the human TSH receptor. J Immunol Methods 2006; 315: 11-8
31. Lo Conte L, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J Mol Biol 1999; 285: 2177-98
32. Wuthrich K. Protein structure determination in solution by NMR spectroscopy. J Biol Chem 1990; 265: 22059-62
33. Johnson MA, Pinto BM. Saturation-transfer difference NMR studies for the epitope mapping of a carbohydrate-mimetic peptide recognized by an anticarbohydrate antibody. Bioorg Med Chem 2004; 12: 295-300
34. Kuntz I, Blaney J, Oatley S, et al. A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982; 161: 269-88
35. Inbar Y, Benyamini H, Nussinov R, et al. Prediction of multimolecular assemblies by multiple docking. J Mol Biol 2005; 349: 435-47
36. Mendez R, Leplae R, De Maria L, et al. Assessment of blind predictions of protein-protein interactions: current status of docking methods. Proteins 2003; 52: 51-67
37. Mendez R, Leplae R, Lensink MF, et al. Assessment of CAPRI predictions in rounds 3-5 shows progress in docking procedures. Proteins 2005; 60: 150-69
38. Gray JJ, Moughon SE, Kortemme T, et al. Protein-protein docking predictions for the CAPRI experiment. Proteins 2003; 52: 118-22
39. Halperin I, Ma B, Wolfson H, et al. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 2002; 47: 409-43
40. Sotriffer CA, Flader W, Winger RH, et al. Automated docking of ligands to antibodies: methods and applications. Methods 2000; 20: 280-91
41. Di Nola A, Roccatano D, Berendsen HJ. Molecular dynamics simulation of the docking of substrates to proteins. Proteins 1994; 19: 174-82
42. Apostolakis J, Caflisch A. Computational ligand design. Comb Chem High Throughput Screen 1999; 2: 91-104
43. Vajda S, Camacho CJ. Protein-protein docking: is the glass half-full or half-empty? Trends Biotechnol 2004; 22: 110-6
44. Wodak SJ, Mendez R. Prediction of protein-protein interactions: the CAPRI experiment, its evaluation and implications. Curr Opin Struct Biol 2004; 14: 242-9
45. Wilson PT, Gershoni JM, Hawrot E, et al. Binding of alpha-bungarotoxin to proteolytic fragments of the alpha subunit of Torpedo acetylcholine receptor analyzed by protein transfer on positively charged membrane filters. Proc Natl Acad Sci U S A 1984; 81: 2553-7
46. Neumann D, Barchan D, Safran A, et al. Mapping of the alpha-bungarotoxin binding site within the alpha subunit of the acetylcholine receptor. Proc Natl Acad Sci U S A 1986; 83: 3008-11
47. Wilson PT, Lentz TL, Hawrot E. Determination of the primary amino acid sequence specifying the alpha-bungarotoxin binding site on the alpha subunit of the acetylcholine receptor from Torpedo californica. Proc Natl Acad Sci U S A 1985; 82: 8790-4
48. Barkas T, Mauron A, Roth B, et al. Mapping the main immunogenic region and toxin-binding site of the nicotinic acetylcholine receptor. Science 1987; 235: 77-80
49. Gershoni JM. () Expression of the alpha-bungarotoxin binding site of the nicotinic acetylcholine receptor by Escherichia coli transformants. Proc Natl Acad Sci U S A 1987; 84: 4318-21
50. Benjamin DC, Perdue SS. Site-directed mutagenesis in epitope mapping. Methods 1996; 9: 508-15
51. Cunningham BC, Wells JA. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 1989; 244: 1081-5
52. Wells JA. Systematic mutational analyses of protein-protein interfaces. Methods Enzymol 1991; 202: 390-411
53. Chakraborti S, Prabakaran P, Xiao X, et al. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2005; 2: 73
54. Cunningham BC, Wells JA. Comparison of a structural and a functional epitope. J Mol Biol 1993; 234: 554-63
55. Dall'Acqua W, Goldman ER, Lin W, et al. A mutational analysis of binding interactions in an antigen-antibody protein-protein complex. Biochemistry 1998; 37: 7981-91
56. Nuss JM, Whitaker PB, Air GM. Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Proteins 1993; 15: 121-32
57. Darbha R, Phogat S, Labrijn AF, et al. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 2004; 43: 1410-7
58. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310: 1025-8
59. Derbyshire KM, Salvo JJ, Grindley ND. A simple and efficient procedure for saturation mutagenesis using mixed oligodeoxynucleotides. Gene 1986; 46: 145-52
60. Fraga D, Fillingame RH. Essential residues in the polar loop region of subunit c of Escherichia coli F1F0 ATP synthase defined by random oligonucleotide-primed mutagenesis. J Bacteriol 1991; 173: 2639-43
61. Matteucci MD, Heyneker HL. Targeted random mutagenesis: the use of ambiguously synthesized oligonucleotides to mutagenize sequences immediately 5′ of an ATG initiation codon. Nucleic Acids Res 1983; 11: 3113-21
62. Ner SS, Goodin DB, Smith M. A simple and efficient procedure for generating random point mutations and for codon replacements using mixed oligodeoxynucleotides. DNA 1988; 7: 127-34
63. Ophir R, Gershoni JM. Biased random mutagenesis of peptides: determination of mutation frequency by computer simulation. Protein Eng 1995; 8: 143-6
64. Shortle D, Nathans D. Local mutagenesis: a method for generating viral mutants with base substitutions in preselected regions of the viral genome. Proc Natl Acad Sci U S A 1978; 75: 2170-4
65. Shugar D, Huber CP, Birnbaum GI. Mechanism of hydroxylamine mutagenesis: crystal structure and conformation of 1,5-dimethyl-N4-hydroxycytosine. Biochim Biophys Acta 1976; 447: 274-84
66. Fried M. Isolation of temperature-sensitive mutants of polyoma virus. Virology 1965; 25: 669-71
67. Shortle D, DiMaio D, Nathans D. Directed mutagenesis. Annu Rev Genet 1981; 15: 265-94
68. Smith M. In vitro mutagenesis. Annu Rev Genet 1985; 19: 423-62
69. Burns EL, Nicholas RA, Price EM. Random mutagenesis of the sheep Na,K-ATPase alpha1 subunit generating the ouabain-resistant mutant L793P. J Biol Chem 1996; 271: 15879-83
70. Wrenn CK, Katzenellenbogen BS. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 1993; 268: 24089-98
71. Brown DM, McNaught AD, Schell P. The chemical basis of hydrazine mutagenesis. Biochem Biophys Res Commun 1966; 24: 967-71
72. Cadwell RC, Joyce GF. Randomization of genes by PCR mutagenesis. PCR Methods Appl 1992; 2: 28-33
73. Prasad L, Sharma S, Vandonselaar M, et al. Evaluation of mutagenesis for epitope mapping: structure of an antibody-protein antigen complex. J Biol Chem 1993; 268: 10705-8
74. Sharma S, Georges F, Delbaere LT, et al. Epitope mapping by mutagenesis distinguishes between the two tertiary structures of the histidine-containing protein HPr. Proc Natl Acad Sci U S A 1991; 88: 4877-81
75. Smith GP, Petrenko VA. Phage display. Chem Rev 1997; 97: 391-410
76. Enshell-Seijffers D, Denisov D, Groisman B, et al. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol 2003; 334: 87-101
77. Oleksiewicz MB, Botner A, Toft P, et al. Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes. J Virol 2001; 75: 3277-90
78. Riemer AB, Kraml G, Scheiner O, et al. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu: a new method of epitope definition. Mol Immunol 2005; 42: 1121-4
79. Enshell-Seijffers D, Smelyanski L, Gershoni JM. The rational design of a 'type 88' genetically stable peptide display vector in the filamentous bacteriophage fd. Nucleic Acids Res 2001; 29: E50
80. Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988; 73: 305-18
81. Fleming TJ, Sachdeva M, Delic M, et al. Discovery of high-affinity peptide binders to BLyS by phage display. J Mol Recognit 2005; 18: 94-102
82. Schreiber A, Humbert M, Benz A, et al. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J Comput Chem 2005; 26: 879-87
83. Zwick MB, Bonnycastle LL, Menendez A, et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol 2001; 75: 6692-9
84. Halperin I, Wolfson H, Nussinov R. SiteLight: binding-site prediction using phage display libraries. Protein Sci 2003; 12: 1344-59
85. Mayrose I, Shlomi T, Rubinstein ND, et al. Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. Nucleic Acids Res 2007; 35 (1): 69-78
86. Bublil EM, Tarnovitski Freund N, Mayrose I, et al. Stepwise prediction of conformational discontinuous B-cell epitopes using the mapitope algorithm. Proteins Structure Function Bioinformatics. In press
87. Bublil EM, Yeger-Azuz S, Gershoni JM. Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120. Faseb J 2006; 20: 1762-74
88. Tarnovitski N, Matthews LJ, Sui J, et al. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol 2006; 359: 190-201